Ovarian Cancer Drug Approval Tops SPT Week in Review

Article

Top news of the week from Specialty Pharmacy Times.

5. Opioid Duration, Not Dosage May Be Key to Reducing Misuse in Surgical Patients

The researchers found that total duration of opioid use was the strongest predictor of misuse, with each refill and additional week of opioid use associated with an increased rate of misuse. Read more.

4. Nearly Half of Patients in Trial Respond to Checkpoint Inhibitor Treatment for Common Skin Cancer

Cemiplimab induced a response in approximately half of patients with advanced cutaneous squamous-cell carcinoma. Read more.

3. Multiple Sclerosis Drug Reduces Disease Activity, Disability Progression in Trials

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis. Read more.

2. FDA OKs Keytruda for Relapsed/Refractory PMBCL, Advanced Cervical Cancer

Pembrolizumab (Keytruda, Merck) gained FDA approval for 2 new oncology indications. Read more.

1. FDA Approves Bevacizumab with Chemotherapy for Ovarian Cancer

Officials with the FDA have approved bevacizumab (Avastin, Genentech) in combination with carboplatin and paclitaxel for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Read more.

Related Videos
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.